Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

Targeting NF- B in Waldenstrom macroglobulinemia

(2008) X. Leleu et al.   BLOOD

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia

(2008) A. M. Roccaro et al.   BLOOD

Thalidomide and rituximab in Waldenstrom macroglobulinemia

(2008) S. P. Treon et al.   BLOOD

Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia

(2008) S. P. Treon et al.   BLOOD

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

(2008) Ruben Niesvizky et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia

(2008) S. P. Treon et al.   CLINICAL CANCER RESEARCH

Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

(2008) Asher Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia

(2008) Meletios Athanasios Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs

(2008) Xavier Leleu et al.   JOURNAL OF CLINICAL ONCOLOGY

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

(2008) C Buske et al.   LEUKEMIA